Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Goodwill & Intangibles (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Goodwill & Intangibles for 16 consecutive years, with $8.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Goodwill & Intangibles fell 70.13% to $8.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $8.1 million, a 70.13% decrease, with the full-year FY2025 number at $8.1 million, down 70.13% from a year prior.
  • Goodwill & Intangibles was $8.1 million for Q4 2025 at Anika Therapeutics, roughly flat from $8.1 million in the prior quarter.
  • In the past five years, Goodwill & Intangibles ranged from a high of $120.9 million in Q2 2021 to a low of $7.2 million in Q2 2022.
  • A 5-year average of $43.9 million and a median of $10.4 million in 2023 define the central range for Goodwill & Intangibles.
  • Biggest YoY gain for Goodwill & Intangibles was 947.37% in 2022; the steepest drop was 94.07% in 2022.
  • Anika Therapeutics' Goodwill & Intangibles stood at $90.2 million in 2021, then skyrocketed by 32.51% to $119.5 million in 2022, then crashed by 91.51% to $10.1 million in 2023, then skyrocketed by 165.7% to $27.0 million in 2024, then tumbled by 70.13% to $8.1 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Goodwill & Intangibles are $8.1 million (Q4 2025), $8.1 million (Q3 2025), and $8.1 million (Q2 2025).